Investor Presentaiton

Q2 2023 UPDATE ON SELECT PRODUCTS Millions $6,000 Growth Products New Products $5,000 $4,000 $3,000 $2,000 $1,000 $0 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 2020 2021 2022 2023 New Products: Jaypirca, Mounjaro, and Omvoh Growth Products: Cyramza, Emgality, Jardiance, Olumiant, Retevmo, Taltz, Trulicity, Tyvyt, and Verzenio Not for promotional use NEW PRODUCTS MOUNJARO • U.S. T2D launch in Q2 2022 Lilly U.S. T2D injectable incretins TRX SOM over 22% at end of Q2 2023 JAYPIRCA • U.S. MCL approval in Q1 2023 OMVOH Japan approval in Q1 2023; EU approval in Q2 2023 GROWTH PRODUCTS JARDIANCE • Market leader in U.S. with TRX SOM over 62% at the end of Q2 • U.S. TRX grew nearly 29% vs. Q2 2022, outpacing the market TALTZ U.S. TRX SOM at 6% at the end of Q2 • U.S. TRx grew over 11% vs. Q2 2022, outpacing the market TRULICITY . U.S. T2D injectable incretins TRX SOM of nearly 26% at the end of Q2 ⚫ U.S. TRx grew nearly 12% vs. Q2 2022 VERZENIO • U.S. TRx grew nearly 60% vs. Q2 2022 • Strong uptake in adjuvant breast cancer indication 2023 Q2 EARNINGS 10

View entire presentation